Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review

Psychiatry Research

Volumn 240, Issue , 2016, Pages 421-430

  De Carlo, Vera ^a   Calati, Raffaella ^b,c   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIV MONTPELLIER   (France)

^c FONDATION FONDAMENTAL   (France)

Author keywords

Antidepressant; Depression; Predictors; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGE; ANXIETY; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITION; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; DRUG RESPONSE; ETHNICITY; FAMILY HISTORY; FATIGUE; GENITAL SYSTEM DISEASE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MARRIAGE; MENOPAUSE; META ANALYSIS; PERSONALITY DISORDER; PREDICTION; PREDICTIVE VALUE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEX DIFFERENCE; SEXUALITY; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT RESISTANT DEPRESSION; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; PERSONALITY;

ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HOSPITALIZATION; HUMANS; PERSONALITY;

EID: 84964813134     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.04.034     Document Type: Review

References (64)

1. Agid O., Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int. J. Neuropsychopharmacol. 2003, 6:41-49.
2. Al-Harbi K.S. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence 2012, 6:369-388.
3. Amsterdam J.D., Garcia-Espana F., Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress. Anxiety 1997, 5:84-90.
4. Ansseau M., Troisfontaines B., Papart P., von Frenckell R. Compulsive personality as predictor of response to serotoninergic antidepressants. BMJ 1991, 303:760-761.
5. Bagby R.M., Rector N.A., Segal Z.V., Joffe R.T., Levitt A.J., Kennedy S.H., Levitan R.D. Rumination and distraction in major depression: assessing response to pharmacological treatment. J. Affect. Disord. 1999, 55:225-229.
6. Bagby R.M., Ryder A.G., Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J. Psychiatry Neurosci. 2002, 27:250-257.
7. Bares M., Novak T., Kopecek M., Stopkova P., Cermak J., Kozeny J., Hoschl C. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. Int. J. Psychiatry Clin. Pr. 2013, 17:35-43.
8. Bares M., Novak T., Kopecek M., Stopkova P., Kozeny J., Hoschl C. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur. Psychiatry 2012, 27:522-527.
9. Bauer M., Tharmanathan P., Volz H.P., Moeller H.J., Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:172-185.
10. Beasley C.M., Sayler M.E., Cunningham G.E., Weiss A.M., Masica D.N. Fluoxetine in tricyclic refractory major depressive disorder. J. Affect. Disord. 1990, 20:193-200.
11. Bergman J., Miodownik C., Palatnik A., Lerner V. Efficacy of bupropion XR in treatment-resistant elderly patients: a case series study. Clin. Neuropharmacol. 2011, 34:17-20.
12. Berlanga C., Ortega-Soto H.A. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J. Affect. Disord. 1995, 34:187-192.
13. Berlim M.T., Fleck M.P., Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann. Med. 2008, 40:149-159.
14. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can. J. Psychiatry 2007, 52:46-54.
15. Berlim M.T., Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur. Neuropsychopharmacol. 2007, 17:696-707.
16. Bock C., Bukh J.D., Vinberg M., Gether U., Kessing L.V. Do stressful life events predict medical treatment outcome in first episode of depression?. Soc. Psychiatry Psychiatr. Epidemiol. 2009, 44:752-760.
17. Cain R.A. Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care. Prim. Care 2007, 34:505-519. (vi).
18. Carvalho A.F., Berk M., Hyphantis T.N., McIntyre R.S. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother. Psychosom. 2014, 83:70-88.
19. Committee for Medicinal Products for Human Use, 2013, Guideline on Clinical investigation of Medicinal Products in the Treatment of Depression.
20. DeBattista C., Solvason H.B., Poirier J., Kendrick E., Schatzberg A.F. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J. Clin. Psychopharmacol. 2003, 23:27-30.
21. Devereaux P.J., Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J. Intern. Med. 2003, 254:105-113.
22. Di Nasso E., Chiesa A., Serretti A., De Ronchi D., Mencacci C. Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. Clin. Drug Investig. 2011, 31:385-405.
23. Dudek D., Rybakowski J.K., Siwek M., Pawlowski T., Lojko D., Roczen R., Kiejna A. Risk factors of treatment resistance in major depression: association with bipolarity. J. Affect. Disord. 2010, 126:268-271.
24. Fang Y., Yuan C., Xu Y., Chen J., Wu Z., Cao L., Yi Z., Hong W., Wang Y., Jiang K., Gao K., Cui X., Nierenberg A.A. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J. Clin. Psychopharmacol. 2010, 30:357-364.
25. Fava M., Alpert J., Nierenberg A., Lagomasino I., Sonawalla S., Tedlow J., Worthington J., Baer L., Rosenbaum J.F. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J. Clin. Psychopharmacol. 2002, 22:379-387.
26. Gaynes B.N., Dusetzina S.B., Ellis A.R., Hansen R.A., Farley J.F., Miller W.C., Sturmer T. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J. Clin. Psychopharmacol. 2012, 32:114-119.
27. Gaynes B.N., Warden D., Trivedi M.H., Wisniewski S.R., Fava M., Rush A.J. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 2009, 60:1439-1445.
28. Howland R.H., Rush A.J., Wisniewski S.R., Trivedi M.H., Warden D., Fava M., Davis L.L., Balasubramani G.K., McGrath P.J., Berman S.R. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009, 99:248-260.
29. Inoue T., Honda M., Kawamura K., Tsuchiya K., Suzuki T., Ito K., Matsubara R., Shinohara K., Ishikane T., Sasaki K., Boku S., Fujisawa D., Ono Y., Koyama T. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:223-227.
30. Jenkins E., Goldner E.M. Approaches to understanding and addressing treatment-resistant depression: a scoping review. Depress. Res. Treat. 2012, 2012:469680.
31. Karp J.F., Whyte E.M., Lenze E.J., Dew M.A., Begley A., Miller M.D., Reynolds C.F. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. J. Clin. Psychiatry 2008, 69:457-463.
32. Keitner G.I., Mansfield A.K. Management of treatment-resistant depression. Psychiatr. Clin. N. Am. 2012, 35:249-265.
33. Kiejna A., Pawlowski T., Dudek D., Lojko D., Siwek M., Roczen R., Rybakowski J.K. The utility of Mood Disorder Questionnaire for the detection of bipolar diathesis in treatment-resistant depression. J. Affect. Disord. 2010, 124:270-274.
34. Maron E., Eller T., Vasar V., Nutt D.J. Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. J. Clin. Psychiatry 2009, 70:1054-1056.
35. Mathys M., Mitchell B.G. Targeting treatment-resistant depression. J. Pharm. Pract. 2011, 24:520-533.
36. Mazeh D., Shahal B., Aviv A., Zemishlani H., Barak Y. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int. Clin. Psychopharmacol. 2007, 22:371-375.
37. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Thase M.E., Davis L., Biggs M.M., Shores-Wilson K., Luther J.F., Niederehe G., Warden D., Rush A.J. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry 2006, 163:1531-1541.
38. Nierenberg A.A., Papakostas G.I., Petersen T., Kelly K.E., Iacoviello B.M., Worthington J.J., Tedlow J., Alpert J.E., Fava M. Nortriptyline for treatment-resistant depression. J. Clin. Psychiatry 2003, 64:35-39.
39. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol. Psychiatry 2008, 63:699-704.
40. Papakostas G.I., Petersen T., Denninger J., Sonawalla S.B., Mahal Y., Alpert J.E., Nierenberg A.A., Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003, 118:39-45.
41. Papakostas G.I., Petersen T., Iosifescu D.V., Roffi P.A., Alpert J.E., Rosenbaum J.F., Fava M., Nierenberg A.A. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003, 118:183-188.
42. Papakostas G.I., Petersen T., Pava J., Masson E., Worthington J.J., Alpert J.E., Fava M., Nierenberg A.A. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J. Nerv. Ment. Dis. 2003, 191:444-449.
43. Papakostas G.I., Petersen T., Worthington J.J., Roffi P.A., Alpert J.E., Fava M., Nierenberg A.A. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int. Clin. Psychopharmacol. 2003, 18:293-296.
44. Papakostas G.I., Petersen T.J., Farabaugh A.H., Murakami J.L., Pava J.A., Alpert J.E., Fava M., Nierenberg A.A. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J. Clin. Psychiatry 2003, 64:1357-1361.
45. Perlis R.H., Alpert J., Nierenberg A.A., Mischoulon D., Yeung A., Rosenbaum J.F., Fava M. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr. Scand. 2003, 108:432-438.
46. Perlis R.H., Iosifescu D.V., Alpert J., Nierenberg A.A., Rosenbaum J.F., Fava M. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics 2004, 45:224-229.
47. Petersen T., Gordon J.A., Kant A., Fava M., Rosenbaum J.F., Nierenberg A.A. Treatment resistant depression and axis I co-morbidity. Psychol. Med. 2001, 31:1223-1229.
48. Petersen T., Hughes M., Papakostas G.I., Kant A., Fava M., Rosenbaum J.F., Nierenberg A.A. Treatment-resistant depression and Axis II comorbidity. Psychother. Psychosom. 2002, 71:269-274.
49. Poirier M.F., Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br. J. Psychiatry 1999, 175:12-16.
50. Preston T.C., Shelton R.C. Treatment resistant depression: strategies for primary care. Curr. Psychiatry Rep. 2013, 15:370.
51. Rosso G., Rigardetto S., Bogetto F., Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J. Affect. Disord. 2012, 136:172-176.
52. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
53. Russell J.M., Koran L.M., Rush J., Hirschfeld R.M., Harrison W., Friedman E.S., Davis S., Keller M. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress. Anxiety 2001, 13:18-27.
54. Sagud M., Mihaljevic-Peles A., Uzun S., Cusa B.V., Kozumplik O., Kudlek-Mikulic S., Mustapic M., Barisic I., Muck-Seler D., Pivac N. The lack of association between components of metabolic syndrome and treatment resistance in depression. Psychopharmacology 2013, 230:15-21.
55. Sajatovic M., DiGiovanni S., Fuller M., Belton J., DeVega E., Marqua S., Liebling D. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. Clin. Ther. 1999, 21:733-740.
56. Schosser A., Serretti A., Souery D., Mendlewicz J., Zohar J., Montgomery S., Kasper S. European Group for the Study of Resistant Depression (GSRD) - where have we gone so far: review of clinical and genetic findings. Eur. Neuropsychopharmacol. 2012, 22:453-468.
57. Serretti A., Chiesa A., Calati R., Perna G., Bellodi L., De Ronchi D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int. Clin. Psychopharmacol. 2009, 24:1-18.
58. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 1999, 9:83-91.
59. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007, 68:1062-1070.
60. Taylor F.B., Prather M.R. The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder. Depress. Anxiety 2003, 18:83-88.
61. Turner L., Shamseer L., Altman D.G., Schulz K.F., Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst. Rev. 2012, 1:60.
62. Uher R., Maier W., Hauser J., Marusic A., Schmael C., Mors O., Henigsberg N., Souery D., Placentino A., Rietschel M., Zobel A., Dmitrzak-Weglarz M., Petrovic A., Jorgensen L., Kalember P., Giovannini C., Barreto M., Elkin A., Landau S., Farmer A., Aitchison K.J., McGuffin P. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br. J. Psychiatry 2009, 194:252-259.
63. Vandenbroucke J.P., von Elm E., Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., Poole C., Schlesselman J.J., Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007, 18:805-835.
64. Wan D.D., Kundhur D., Solomons K., Yatham L.N., Lam R.W. Mirtazapine for treatment-resistant depression: a preliminary report. J. Psychiatry Neurosci. 2003, 28:55-59.